Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro

doi:10.1007/s00066-019-01499-6

Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Claudia Scherl, Marlen Haderlein, Abbas Agaimy, Konstantinos Mantsopoulos, Michael Koch, Maximilian Traxdorf, Rainer Fietkau, Philipp Grundtner, Heinrich Iro

Department of Otorhinolaryngology

Research output: Contribution to journal › Original Article › peer-review

7 Citations (Web of Science)

Original language	English
Pages (from-to)	1059
Journal	STRAHLENTHERAPIE UND ONKOLOGIE
Volume	195
Issue number	12
DOIs	https://doi.org/10.1007/s00066-019-01499-6
Publication status	Published - 2019

Keywords

DISTANT METASTASES
PAROTID-GLAND
PROGNOSTIC-FACTORS
NODAL METASTASIS
CARCINOMA
CANCER
TUMORS
SURVIVAL
BRACHYTHERAPY
MALIGNANCIES

Access to Document

10.1007/s00066-019-01499-6

Cite this

Scherl, C., Haderlein, M., Agaimy, A., Mantsopoulos, K., Koch, M., Traxdorf, M., Fietkau, R., Grundtner, P., & Iro, H. (2019). Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy. STRAHLENTHERAPIE UND ONKOLOGIE , 195(12), 1059. https://doi.org/10.1007/s00066-019-01499-6

Scherl, Claudia ; Haderlein, Marlen ; Agaimy, Abbas et al. / Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy. In: STRAHLENTHERAPIE UND ONKOLOGIE 2019 ; Vol. 195, No. 12. pp. 1059.

@article{3c350bb88b1a4ea6957e41f1c1884181,

title = "Outcome and management of rare high-grade {"}salivary{"} adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.",

keywords = "DISTANT METASTASES, PAROTID-GLAND, PROGNOSTIC-FACTORS, NODAL METASTASIS, CARCINOMA, CANCER, TUMORS, SURVIVAL, BRACHYTHERAPY, MALIGNANCIES",

author = "Claudia Scherl and Marlen Haderlein and Abbas Agaimy and Konstantinos Mantsopoulos and Michael Koch and Maximilian Traxdorf and Rainer Fietkau and Philipp Grundtner and Heinrich Iro",

year = "2019",

doi = "10.1007/s00066-019-01499-6",

language = "English",

volume = "195",

pages = "1059",

journal = "STRAHLENTHERAPIE UND ONKOLOGIE ",

issn = "0179-7158",

publisher = "Springer Nature",

number = "12",

}

Scherl, C, Haderlein, M, Agaimy, A, Mantsopoulos, K, Koch, M, Traxdorf, M, Fietkau, R, Grundtner, P & Iro, H 2019, 'Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.', STRAHLENTHERAPIE UND ONKOLOGIE , vol. 195, no. 12, pp. 1059. https://doi.org/10.1007/s00066-019-01499-6

Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy. / Scherl, Claudia; Haderlein, Marlen; Agaimy, Abbas et al.
In: STRAHLENTHERAPIE UND ONKOLOGIE , Vol. 195, No. 12, 2019, p. 1059.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

AU - Scherl, Claudia

AU - Haderlein, Marlen

AU - Agaimy, Abbas

AU - Mantsopoulos, Konstantinos

AU - Koch, Michael

AU - Traxdorf, Maximilian

AU - Fietkau, Rainer

AU - Grundtner, Philipp

AU - Iro, Heinrich

PY - 2019

Y1 - 2019

KW - DISTANT METASTASES

KW - PAROTID-GLAND

KW - PROGNOSTIC-FACTORS

KW - NODAL METASTASIS

KW - CARCINOMA

KW - CANCER

KW - TUMORS

KW - SURVIVAL

KW - BRACHYTHERAPY

KW - MALIGNANCIES

U2 - 10.1007/s00066-019-01499-6

DO - 10.1007/s00066-019-01499-6

M3 - Original Article

C2 - 31350567

SN - 0179-7158

VL - 195

SP - 1059

JO - STRAHLENTHERAPIE UND ONKOLOGIE

JF - STRAHLENTHERAPIE UND ONKOLOGIE

IS - 12

ER -

Scherl C, Haderlein M, Agaimy A, Mantsopoulos K, Koch M, Traxdorf M et al. Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy. STRAHLENTHERAPIE UND ONKOLOGIE . 2019;195(12):1059. doi: 10.1007/s00066-019-01499-6